Theralase Technologies Inc. (CVE:TLT – Get Free Report) shares dropped 1.6% during trading on Friday . The company traded as low as C$0.29 and last traded at C$0.30. Approximately 41,605 shares changed hands during trading, a decline of 70% from the average daily volume of 138,317 shares. The stock had previously closed at C$0.31.
Theralase Technologies Price Performance
The company has a debt-to-equity ratio of 20.58, a current ratio of 1.21 and a quick ratio of 3.40. The stock has a market capitalization of C$73.66 million, a price-to-earnings ratio of -15.00 and a beta of 1.36. The company has a 50-day simple moving average of C$0.27 and a two-hundred day simple moving average of C$0.22.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Further Reading
- Five stocks we like better than Theralase Technologies
- The 3 Best Fintech Stocks to Buy Now
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- 5 discounted opportunities for dividend growth investors
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- What Investors Need to Know About Upcoming IPOs
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
